Renaissance Technologies LLC Cuts Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Renaissance Technologies LLC cut its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 2.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 510,900 shares of the biotechnology company’s stock after selling 15,200 shares during the period. Renaissance Technologies LLC owned 2.41% of Enanta Pharmaceuticals worth $6,626,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quest Partners LLC purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $146,000. Pennant Investors LP purchased a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $330,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $118,000. Vanguard Group Inc. boosted its position in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after buying an additional 134,292 shares during the period. Finally, Acadian Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 1.3% in the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after buying an additional 10,952 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Scott T. Rottinghaus sold 4,299 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the transaction, the insider now directly owns 23,988 shares in the company, valued at $361,499.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Scott T. Rottinghaus sold 5,375 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now owns 21,717 shares in the company, valued at $370,926.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott T. Rottinghaus sold 4,299 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now owns 23,988 shares in the company, valued at $361,499.16. The disclosure for this sale can be found here. Company insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $10.67 on Thursday. The company has a market capitalization of $226.10 million, a P/E ratio of -1.71 and a beta of 0.59. The company has a 50-day moving average of $12.87 and a 200-day moving average of $13.50. Enanta Pharmaceuticals, Inc. has a 1-year low of $8.08 and a 1-year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The firm had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. During the same period in the previous year, the company earned ($1.27) earnings per share. Enanta Pharmaceuticals’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -5.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ENTA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. lowered their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.